Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression. Charalampous C, Doucette K, Chappell A, Vesole DH, et al. Leuk Lymphoma 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647.

Read + Share

Amedeo Smart

Independent Medical Education

Charalampous C, Doucette K, Chappell A, Vesole DH, et al. Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression. Leuk Lymphoma 2024 Aug 1:1-4. doi: 10.1080/10428194.2024.2381647.
PMID: 39088749